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The establishment of pregnancy requires a successful molecular interaction between the trophectoderm cells of the blastocyst stage embryo and
the endometrial cells of the uterus. These interactions are complex and require synchronous development and coordinated endocrine, paracrine,
and autocrine communication. In this study, we demonstrate that the tetraspan protein epithelial membrane protein-2 (EMP2) is involved in these
molecular interactions during implantation. EMP2, which is highly expressed in the uterus, translocates from an intracellular location to the apical
surface of the endometrial epithelium during the window of implantation and is expressed in decidualized stromal cells. We developed plasmid
constructs that utilized either ribozyme-mediated or short hairpin RNA-mediated mechanisms to target endometrial EMP2 mRNA for destruction.
These constructs were transfected into the mouse uterus on day 1 of pregnancy using the technique of in vivo reproductive tract gene transfer.
Reduction in EMP2 expression by either method resulted in a significant decrease in the number of implantation sites in the treated uterine horns
as compared to control horns. These studies indicate a previously unknown function of tetraspan proteins in implantation and could provide a
molecular framework for the development of therapeutic modalities for both contraception and fertility.
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The “window of implantation” is defined as the time of the
menstrual cycle when the uterus supports blastocyst attachment
and implantation (Psychoyos, 1986; Robertson et al., 2001). In
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doi:10.1016/j.ydbio.2006.01.015day menstrual cycle, which in the mouse corresponds to 4–5
days postcoitum (pc) (Suzuki et al., 2000). The window of
implantation is characterized by morphological alterations in
the appearance of the uterine epithelium that include loss of
microvilli and flattening of the apical membranes (Murphy,
2004). In addition, the epithelial cells develop apical surface
protrusions known as “uterodomes” whose presence correlates
well with the period of endometrial receptivity (Adams et al.,
2001). These morphological alterations occur in response to the
effects of progesterone on an estrogen-primed endometrium and
do not require the presence of an implanting blastocyst (Png and
Murphy, 2000).
Although some molecules involved in implantation have
been identified, including Hox proteins, integrins, and selectins
(Bagot et al., 2000; Genbacev et al., 2003; Lessey, 2002; Paria
et al., 2002), a unifying mechanism to explain the coordinate
expression of specific surface proteins during the implantation
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fibroblast and B cell lymphoma cell lines, we demonstrated that
epithelial membrane protein-2 (EMP2), a tetraspan protein in
the GAS3/PMP22 family, can regulate the cell surface
expression of a number of proteins including integrins α5β1
and α6β1 and class I major histocompatibility complex proteins
(Wadehra et al., 2002, 2003a, 2004). These EMP2-regulated
alterations in cell surface protein expression are accompanied
by corresponding alterations in cell–matrix and cell–cell
interactions.
Given the relatively high level of expression of EMP2 in the
uterus (Wang et al., 2001) and the connection between EMP2
and the expression of various cell surface proteins, we
hypothesized that EMP2 might have a significant role during
implantation. Here, we report that, in the mouse, EMP2 is most
highly expressed on the apical endometrial surface during the
window of implantation. To determine if EMP2 had an essential
function during implantation, we utilized two different
strategies to “knock down” EMP2 expression in the mouse
uterus. Plasmid constructs were developed that utilized either
ribozyme-mediated or short hairpin RNA-mediated mechan-
isms to target EMP2 mRNA for destruction. These constructs
were transfected into the mouse uterus on day 1 of pregnancy
using the technique of in vivo reproductive tract gene transfer
(Daftary and Taylor, 2003). Both of the constructs successfully
inhibited expression of endometrial EMP2 protein by day 5 of
pregnancy, and both resulted in a significant decrease in the
ability of blastocysts to implant. These studies strongly suggest
a requirement for EMP2 in implantation in the mouse.
Materials and methods
Animals
All animals used in this study were maintained in accordance with the
National Academy of Science Guide for the Care and Use of Laboratory
Animals, with a controlled light schedule (14L:10D) and controlled temperature
range. Female CF-1 mice (Harlan Sprague–Dawley, Indianapolis, Indiana) were
housed individually with single B6D2F1/J males (Jackson Laboratory, Bar
Harbor, ME) and checked each morning for a vaginal plug. The day of the
vaginal plug was recorded as day 1 pc. For some experiments, females were
superovulated by IP administration of 5 IU pregnant mare's serum gonadotropin
(PMSG; Calbiochem, San Diego, California) followed 48 h later by 5 IU human
chorionic gonadotropin (hCG; Sigma, St. Louis, Missouri) and then housed with
males overnight as above. Females without evidence of a vaginal plug the
following morning were not utilized for subsequent experiments.
Antibodies
Rabbit polyclonal antibodies were generated against murine EMP2
(mEMP2) or human EMP2 (hEMP2); these antisera have been described
previously (Wadehra et al., 2003b; Wang et al., 2001). The corresponding
preimmune sera or pooled rabbit sera were used as controls.
Immunohistochemistry
Uteri were fixed in 4% paraformaldehyde or 10% formalin then paraffin-
embedded and sectioned. Antigen exposure was accomplished by incubating
the slides at 95°C for 20 min in 0.1 M citrate, pH 6.0. Immunohistochemistry
was performed using primary mEMP2 antiserum (1:250) or the same dilution
of either the corresponding preimmune control serum or pooled rabbit sera(Vector Labs Inc., Burlingame, CA). Detection was performed using either a
Vectastain ABC kit (Vector Labs Inc, Burlingame, California) or a DAKO
LSAB2 kit (Dako, Carpenteria, California) according to the manufacturers'
instructions. Microtome sections were also processed for conventional




A murine EMP2 hammerhead ribozyme (mEMP2-RZ1) has been described
previously (Wadehra et al., 2002). This ribozyme sequence is inserted into
pEGFP-N3 and will be referred to as pEGFP-mRZ1. To construct a human
EMP2-specific ribozyme, the following two sets of complementary 42 bp










These oligonucleotides contain the 22 bases of the hammerhead ribozyme
conserved catalytic core, a small region of pEGFP-N3 (Clontech) sequence, and
two 10-nucleotide recognition domains (underlined; based on nucleotides 256–
276 and 376–396 of the human EMP2 sequence; GenBank accession no.
NM001424). The ribozyme sequences were introduced into pEGFP-N3 using
PCR and will be referred to as pEGFP-hRZ1 and pEGFP-hRZ2.
shRNA constructs
A PCR-based strategy (PCR SHAGging) for generating RNA polymerase III
(U6 snRNA promoter)-driven constructs expressing 29 bp short hairpin RNA
(shRNA) targeting mouse or human EMP2 was employed (www.cshl.org/
public/SCIENCE/hannon.html). The human U6 promoter from pGEM-Zeo-U6
(generous gift of Gregory Hannon, Cold Spring Harbor Laboratory, Cold
Spring, NY) was amplified using a forward primer 5′-GATTTAGGTGACAC-
TATAG-3′ (SP6 promoter sequence) and one of two reverse primers (shRNA
sequences underlined, U6 promoter sequences in bold):
Mouse EMP2 (targets nucleotides 260–288; GenBank accession no.
NM007929): 5′-AAAAAAAACACGATGCGGAAGACAATAATGAAGAC-
CAAGCTTCGCCTTCATCATTGTCTTCCACATCGTGTCGGTGTTTCGT-
CCTTTCCACAA-3′; human EMP2 (targets nucleotides 508–536; GenBank
accession no. NM001424): 5′-AAAAAAA GAAGCCGCAATCATAACACAC-
AGACACG CAAGCTTCCATGTCTGTGTGTCATGATTGCGGCCTCC-
GGTGTTTCGTCCTTTCCACAA-3′. PCR was performed using puReTaq
Ready-To-Go PCR Beads (Amersham Biosciences, Piscataway, NJ) in a 25-μl
reaction as follows: an initial denaturation step at 95°C for 5 min followed by 30
cycles at 95°C for 30 s, 52°C for 30 s, and 72°C for 20 s, and then 72°C for 5 min.
The PCR product was TA-cloned into pCR II (Invitrogen, Carlsbad, CA). The
resulting constructs will be referred to as m-shRNA and h-shRNA for the vectors
targeting mouse or human EMP2, respectively.
Cell lines and transfection
HEC1A cells (ATCC, Manassas, VA) were cultured in McCoy's 5a medium
(Invitrogen Life Technologies) supplemented with 10% fetal calf serum
(Hyclone Laboratories, Logan, Utah), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 U/ml penicillin, and 100 U/ml streptomycin (all from Invitrogen
Life Technologies). RL95-2 cells (ATCC) were cultured in a 1:1 mixture of
Dulbecco's modified Eagle's medium and Ham's F12 medium supplemented
with 10 mMHEPES, 2.0 g/l sodium bicarbonate, 0.005 mg/ml insulin, 10% fetal
calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and
100 U/ml streptomycin.
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pEGFP-hRZ2 using FuGENE 6 (Roche Molecular Biochemicals, Indianapolis,
Indiana). Stable HEC1A clones were selected using Geneticin (800 μg/ml,
Invitrogen Life Technologies); these stable cell lines will be referred to as
HEC1A-GFP, HEC1A-hRZ1, and HEC1A-hRZ2, respectively. Stable clones
were similarly generated for RL95-2 cells. NIH 3T3 cells stably expressing a
FLAG-tagged murine EMP2 were established and cultured as previously
described (Wang et al., 2001). The cells were transfected with pCRII, m-shRNA,
or h-shRNA using FuGENE 6 (Roche) according to the manufacturer's
instructions.
Western blot analysis
Cells were washed in PBS, collected, and resuspended in Laemmli buffer.
When appropriate, the cell extracts were treated with peptide N-glycosidase F
(New England Biolabs, Beverly, Massachusetts) to deglycosylate the proteins as
previously described (Wadehra et al., 2002). The lysates were separated on a
12.5% SDS-PAGE gel, and proteins were transferred to nitrocellulose. Protein
loading and transfer were detected on nitrocellulose membranes by Ponceau S
staining (Sigma). EMP2 was detected using primary hEMP2 (1:2000) or
mEMP2 (1:1000) antisera, as appropriate, and secondary horseradish-peroxi-
dase-conjugated goat anti-rabbit IgG (Transduction Laboratories, Lexington,
Kentucky). Actin was detected using primary monoclonal anti-β actin (Sigma
cat# A-5441; 1:12,000 dilution) and secondary horseradish-peroxidase-
conjugated sheep anti-mouse IgG (Amersham). The secondary antibodies
were detected using ECL detection reagents (Amersham).
Blastocyst attachment assay
HEC1A-GFP, HEC1A-hRZ1, HEC1A-hRZ2 cells, and nontransfected
HEC1A cells were grown to confluence in Costar 24-well tissue culture plates
(Corning Inc., Corning, NY). Blastocyst stage mouse embryos were flushed
from the uteri of superovulated, mated females and then cultured in vitro in
KSOM medium (Specialty Media, Phillipsburg, NJ) to allow hatching. Cells
were washed with Dulbecco's PBS (Invitrogen Life Technologies) and then
cultured in medium not containing G418. A single hatched blastocyst was
placed in each well. After 3 days of culture, attachment of each blastocyst to the
underlying cells was examined using transmitted light microscopy. A blastocyst
was considered “attached” if no movement was seen with gentle shaking of the
plate. Either free-floating or mobile blastocysts were considered “not attached”.
Inhibition of uterine EMP2 expression and evaluation of implantation
in vivo
Liposome-mediated plasmid transfection in vivo was a modification of a
method described previously (Bagot et al., 2000; Daftary and Taylor, 2003).
DNA–liposome preparations were made immediately prior to the transfection
surgery by mixing the appropriate plasmid DNA with FuGENE 6 (Roche
Molecular Biochemicals, Indianapolis, Indiana) in a 1:3 (μg:μl) ratio as per the
manufacturer's instructions. The quantity of plasmid DNA used for each
experiment is indicated in the text or figure legends. After incubation for 15 min,
sterile PBS was added to the DNA–liposome mixture such that the DNA to be
injected was in a final volume of 100 μl, and the mixture was drawn into a 1 ml
syringe. In the afternoon of day 1 pc, females were anesthetized and the distal
portion of each uterine horn was identified via small flank incisions (Hogan et
al., 1994). The uterine horns each were slowly injected via a 30-G needle with
100 μl of the appropriate DNA–liposome mixture. Luminal placement of the
injected fluid was confirmed by observation of slight distension of the visible
portion of the uterine horn.
The details of the mechanics of this method are worth mentioning here. In
test experiments on CF1 mice in which the entire reproductive tract was exposed
via an abdominal incision, the capacity of a uterine horn was only about 20 μl.
Injected fluid above this volume leaked rapidly into the vagina. This finding
indicated that the maximal dose of plasmid DNA to which the uterine horn could
be exposed was approximately 20% of the original amount in the DNA–
liposome mixture. However, it is unlikely that even a 20 μl fluid volume would
remain in the uterine horn long-term, so perhaps a better way to consider themethod is that it is a brief exposure to a specific concentration of DNA. In other
words, the uterine epithelium was exposed briefly to a flow of 100 μl of fluid
containing 0.20, 0.10, or 0.05 μg DNA/μl at the 20, 10, and 5 μg plasmid DNA
doses, respectively. When injections were performed with Coomassie Blue dye
to track the injected fluid, no dye was observed to enter the contralateral uterine
horn. However, because of the possibility of crossover of the fluid into the
opposite uterine horn, the first horn injected was the “treatment” horn, and the
second horn was injected with the control DNA so that any crossover fluid
would be washed out of the control horn. This method was chosen over using
different mice for each type of DNA so that each mouse could serve as its own
internal control.
For experiments to assess the efficacy of the transfected plasmids in
reducing EMP2 expression, females were euthanized 4 days after
transfection (day 5 pc) and the uteri were processed for immunohistochem-
istry using mEMP2 antisera or the corresponding preimmune control. For
the implantation experiments, females were euthanized 1 week later (day
8 pc), and the number of visible implantation sites in each uterine horn was
counted. Unless otherwise indicated, a total of at least 10 females were
evaluated in at least three independent experiments. Mice that had vaginal
plugs and surgery that were not pregnant at all were excluded from the
analysis.
Statistical methods
Differences in blastocyst attachment in vitro were evaluated by Chi-square
tests, and differences in the numbers of implantation sites in vivo were evaluated
by a Wilcoxon matched pairs test using Prism 4 (GraphPad Software, San
Diego, CA).Results
Expression of EMP2 in the mouse uterus
To determine if EMP2 could be involved in implantation,
EMP2 expression and localization in the uterus were examined
in non-hyperstimulated, mated mice before (day 1 pc) and
during (day 4 pc) the “window of implantation” (Fig. 1). On day
1 pc, EMP2 was expressed in both the luminal and glandular
endometrial epithelium in the supranuclear region of the
intracellular compartment, in a pattern consistent with a
Golgi/endoplasmic reticulum (ER) distribution (Figs. 1A–C).
At this time, no EMP2 staining was detected in the endometrial
stroma. On day 4 pc, EMP2 was still expressed mainly in the
supranuclear region of the intracellular compartment of the
luminal and glandular epithelium, but the staining was more
diffuse (Figs. 1D–F). In the luminal epithelium, EMP2 was
found localized to the apical cell surface; this localization
pattern was present in glandular epithelium as well but was not
as dramatic. In addition, EMP2 was expressed in the stroma by
day 4 pc.
EMP2 expression was also examined in the early post-
implantation period. On day 6 pc, the decidualized stromal cells
at the site of implantation expressed relatively high levels of
EMP2 (Fig. 2). EMP2 expression in decidual cells of the inter-
implantation sites was similar to that around the implanting
embryos (data not shown). In addition, high EMP2 expression
was noted in embryonic trophectoderm cells (Figs. 2C, D). The
decidual expression of EMP2 persisted through day 7 pc (Figs.
2E, F), but it was decreased qualitatively at this time as
compared to day 6 pc. These experiments established that,
during early pregnancy, the peri-implantation period was the
Fig. 1. EMP2 expression and localization in the mouse uterus before implantation. Mouse uteri were obtained on day 1 pc (A–C) or day 4 pc (D–F) and then fixed and
processed for immunohistochemistry using mEMP2 antiserum. Magnification: 100× (A, D); 200× (B, E); 400× (C, F).
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epithelial and stromal cells.
Because we wanted to use ovarian hyperstimulation to
synchronize the mouse estrous cycles in later experiments (to
assist in the timing of mating and surgical procedures and to
increase the number of possible implantation sites per uterine
horn), we needed to determine if EMP2 expression was similar
in normally cycling and hyperstimulated mice. Uteri were
collected at 24-h intervals after initiating hyperstimulation
treatment and ending day 5 pc. On day 1 after PMSG treatment,
EMP2 was expressed on the apical side of the nuclei of the
luminal epithelium, similar to unstimulated mice, but some
EMP2 was also seen on the apical cell surface (Fig. 3B). By 48
h after PMSG, the overall level of EMP2 staining was
diminished, although some staining was present in the supra-
nuclear region (Fig. 3C). On days 1 and 2 pc, EMP2 staining
increased in the supranuclear region and was found throughout
the cytoplasm of the epithelial cells (Figs. 3D, E). On day 3 pc,
EMP2 staining was present diffusely throughout the cytoplasm
of the epithelial cells and had begun to accumulate at the apical
surface of the luminal epithelium (Fig. 3F). By days 4–5 pc,
EMP2 staining was dramatically increased at the apical cell
surface of luminal and glandular epithelium (Figs. 3G, H).Similar to non-hyperstimulated mice, EMP2 expression in the
endometrial stroma was noted at this time. At all time points, the
glandular epithelium exhibited a staining pattern similar to that
of the luminal epithelium (data not shown). These data
demonstrated that, in both normally cycling and hyperstimu-
lated mice, EMP2 had the temporal and spatial expression
pattern in the endometrium consistent with that of the protein
involved in implantation.
EMP2 expression and modulation in human endometrial cell
lines
Human endometrial carcinoma cell lines have been used
previously as in vitro models of uterine epithelium for the study
of implantation (Hohn et al., 2000; Thie and Denker, 2002;
Tinel et al., 2000). We hypothesized that if EMP2 were
important for implantation then it would be expressed in these
cell lines and that its expression could be modulated prior to
using the cells for in vitro attachment assays. We chose two cell
lines for these in vitro assays: HEC1A cells, which support
trophoblast attachment in the presence of serum, and RL95-2
cells, which efficiently support trophoblast attachment in the
presence or absence of serum (Thie et al., 1995). Endogenous
Fig. 2. EMP2 expression and localization in the mouse uterus after implantation. Mouse uteri were obtained on day 6 pc (A–D) and day 7 pc (E–F) and then fixed and
processed for immunohistochemistry using control pooled rabbit sera (A, B) or mEMP2 antiserum (C–F). e, embryo; d, decidua; te, trophectoderm cells.
Magnification: 100× (A, C, E); 400× (B, D, F).
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HEC1A and RL95-2 cells. Although both cell lines expressed
EMP2, the level of EMP2 in RL95-2 cells was much higher
(Fig. 4A).
We previously developed a ribozyme-containing vector that
targeted mouse EMP2 for destruction (Wadehra et al., 2002).
For this study, we generated a similar ribozyme designed to
target human EMP2 and tested its effect on expression of EMP2
in HEC1A and RL95-2 cells. HEC1A cells were stably
transfected with a vector containing one of two human
EMP2-specific ribozymes (HEC1A-hRZ1, HEC1A-hRZ2) or
a vector control (HEC1A-GFP). Although both of the ribozyme
constructs reduced EMP2 expression, the hRZ1 construct was
somewhat more effective than hRZ2 (Fig. 4B). The efficacy of
the hRZ1 construct was confirmed in RL95-2 cells as well by
performing a transfection with the pEGFP vector control or
pEGFP-hRZ1. The transfection efficiency after selection in both
cultures was estimated at 80% based on counts of the number of
cells expressing EGFP. Immunoblot analysis revealed an
obvious decrease in EMP2 expression in the cells over-
expressing EGFP-hRZ1 when compared to EGFP alone (Fig.
4C). These results documented that the hRZ1 and hRZ2
constructs encoded functional ribozymes.Effect of modulating EMP2 expression on blastocyst
attachment in vitro
To determine if alterations in the level of EMP2 expression
in HEC1A cells affected their ability to support blastocyst
adhesion, we performed in vitro attachment assays using intact
hatched mouse blastocysts. Although it was a heterologous
system, mouse blastocysts were utilized for these assays (rather
than JAR spheroids made from choriocarcinoma cells) to
provide a closer approximation to the blastocyst–endometrium
interaction that occurs in vivo. Blastocysts were placed onto
confluent monolayers of untransfected HEC1A, HEC1A-GFP,
HEC1A-hRZ1, or HEC1A-hRZ2 cells, and evaluated for
attachment to the underlying cells. HEC1A cells expressing
either of the ribozyme constructs had significantly reduced
blastocyst attachment when compared to the controls (Table 1).
Whereas 42% (31/74) of the blastocysts attached to HEC1A-
GFP cells, only 4% (3/68) blastocysts attached to the HEC1A-
hRZ1 cells. Of note, there was a correlation between the level of
EMP2 expression and blastocyst attachment—intermediate
EMP2 expression in the HEC1A-hRZ2 cells (Fig. 4B) was
associated with an intermediate level of inhibition of blastocyst
attachment (25%, 18/71). Untransfected HEC1A and HEC1A-
Fig. 3. EMP2 expression and localization in the mouse uterus after hyperstimulation. Mouse uteri were obtained at the indicated times after PMSG or hCG
administration and mating then fixed and processed for immunohistochemistry using either preimmune serum (A) or mEMP2 antiserum (B–H). Magnification: 400×.
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transfection of these cells did not alter their adhesive properties.
To confirm these findings, we performed similar experiments
using RL95-2 cells. Reduction of EMP2 expression in RL95-2
cells by transfection with hRZ1 yielded results similar to those
obtained using HEC1A cells, with a 50% reduction in blastocyst
attachment compared to GFP-transfected control cells (data not
shown). These data demonstrated that a reduction of EMP2
expression in human endometrial epithelial cells effectively
inhibited the attachment of intact mouse blastocysts in vitro.
Effect of modulating EMP2 expression on blastocyst
attachment in vivo
To determine if EMP2 was involved in implantation in vivo,
we utilized the mouse ribozyme construct to reduce EMP2
protein levels in the mouse endometrium during the peri-
implantation period. These experiments were based on previous
work demonstrating that liposome-mediated gene transfection
is an effective method for in vivo gene transfer to the mouse
reproductive tract and can be used to define functional roles for
proteins involved in implantation (Bagot et al., 2000). The
uterine horns of hyperstimulated, mated mice were transfectedon day 1 pc with ribozyme-containing or control plasmids. The
rationale for this timing for the transfection was that it would
maximize the time available for turnover of pre-existing EMP2
protein to occur following mRNA destruction induced by the
ribozyme, thereby achieving the greatest degree of protein
knockdown possible without disrupting the mating process.
Furthermore, it maximized the time for recovery of the uterine
epithelium from any potential disruptive effects of the
transfection procedure. In each experiment, the opposite uterine
horn in the same mouse was used as a control to eliminate any
bias due to possible differences in the numbers of implanting
embryos or differences in nonspecific effects of anesthesia or
the surgical procedure itself. There was a dose-dependent
decrease in EMP2 expression in the luminal epithelium by day 5
pc in response to transfection with either 5 or 20 μg pEGFP-
mRZ1 (Figs. 5B, C). Control uterine horns transfected with
either 5 or 20 μg pEGFP (Figs. 5E, F) expressed EMP2 at levels
similar to that of horns transfected with diluent and FuGENE 6
(no DNA; Fig. 5A). These data confirmed that the mRZ1
ribozyme effectively decreased expression of EMP2 in the
endometrium in vivo.
The effect of reducing EMP2 expression on implantation
was assessed on day 8 pc, 7 days after the transfection surgery.
Fig. 4. Expression and modulation of EMP2 expression in human endometrial
cells. (A) Immunoblot analysis of EMP2 expression in human endometrial cell
lines. Equivalent amounts of cell lysates (30 μg) from RL95-2 and HEC1A cells,
as indicated, were immunoblotted with hEMP2 antiserum (upper panel). The
same blot was reprobed using a monoclonal anti-actin antibody (lower panel).
(B) Immunoblot analysis of EMP2 expression in stably transfected HEC1A-
GFP, HEC1A-hRZ1, and HEC1A-hRZ2 cells, as indicated (upper panel). The
same blot was stained using Ponceau S (lower panel). (C) Immunoblot analysis
of EMP2 expression in RL95-2 cells transfected with either pEGFP or pEGFP-
hRZ1, as indicated (upper panel). The same blot was reprobed for actin (lower
panel).
Table 1
Blastocyst attachment to HEC1A cells expressing different levels of EMP2
Attached Not attached
No DNA 39/78 (50%) 39/78 (50%)
GFP 31/74 (42%) 43/74 (58%)
hRZ1 a 3/68 (4%) 65/68 (96%)
hRZ2b 18/71 (25%) 53/71 (75%)
a Significant differences between the hRZ1 and GFP cells (Chi-square,
P b 0.0001).
b Significant differences between the hRZ2 and GFP cells (Chi-square,
P b 0.05).
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shown (Figs. 6A, B). There were striking differences in the
number of implantation sites in the pEGFP-mRZ1-transfected
uterine horns as compared to the pEGFP-transfected horns (Fig.
6C). No visible implantation sites were observed in uterine
horns transfected with 20 μg pEGFP-mRZ1, whereas multiple
implantation sites were present in the control horns transfected
with the same amount of pEGFP. An intermediate number of
implantation sites was seen when 5 or 10 μg pEGFP-mRZ1 was
used as compared to the same quantity of pEGFP, suggesting a
dose-dependent response.
There were no significant differences between the number of
implantation sites in control nontransfected and pEGFP-
transfected uterine horns, however, there was a trend toward a
reduction in implantation sites at the higher doses of pEGFP
(compare the no DNA control to 5, 10, or 20 μg GFP; Fig. 6C).
It is possible that this reduction was caused by migration of the
ribozyme into the control horn. Alternatively, it is possible that
the higher doses of DNA could induce a nonspecific
endometrial inflammatory response. We do not believe thatthis reduction in implantation sites alters the conclusions of this
study because the control horns were transfected with the same
amount of DNA and liposome as the experimental horns, and
therefore the nonspecific effects should be similar in the two
groups.
To ensure that the effect on implantation was due to the
decrease in EMP2 protein and not a nonspecific effect of
expressing a functional ribozyme, mouse uterine horns were
transfected with 20 μg of the human EMP2-specific ribozyme
(pEGFP-hRZ1) that cannot target mouse EMP2 (because the
EMP2 recognition sequences in the human ribozyme differ
from those in the mouse ribozyme). There was no significant
difference between the number of implantation sites in the
pEGFP-hRZ1-transfected and uterine horns transfected with a
pEGFP control plasmid (mean ± SEM of 4.1 ± 1.9 and 6.6 ± 1.8,
respectively, N = 8, P = 0.25).
Although these experiments strongly suggested that EMP2
was required for implantation, we wanted to corroborate this
finding using an alternate method of decreasing EMP2
expression in vivo. Plasmid constructs containing short hairpin
RNA sequences driven by the human U6 RNA polymerase III
promoter were generated to target either mouse or human
EMP2. The mouse shRNA plasmid (m-shRNA) was tested for
efficacy in vitro using NIH 3T3 cells overexpressing mouse
EMP2. This construct was found to reduce EMP2 expression 48
h after transfection more than two-fold when compared to cells
transfected with either pCRII alone or h-shRNA, even though
the constructs were only transiently expressed (Fig. 7). This
finding verified that the m-shRNA sequence chosen was
effective and that the control h-shRNA sequence had no effect
on mouse EMP2 expression in these cells.
To determine if the shRNA constructs would similarly affect
expression of EMP2 in vivo, uterine horns of hyperstimulated
and mated mice were transfected on day 1 pc with either m-
shRNA or h-shRNA (control). Again, the opposite uterine horn
in the same mouse was used for the control plasmid to eliminate
confounding effects of using different mice for different
constructs. In response to transfection with 10 μg m-shRNA,
there was a significant decrease in EMP2 expression in the
luminal epithelium by day 5 pc when compared to horns
transfected with 10 μg h-shRNA (Fig. 8). These data confirmed
that the mouse EMP2-specific shRNA construct effectively
decreased expression of EMP2 in vivo. On day 8 pc, the mean
number of implantation sites in the m-shRNA horns was
Fig. 5. Effect of ribozyme transfection on EMP2 expression in mouse endometrium. Uterine horns were transfected on day 1 pc with PBS/FuGENE alone (A, D) or the
indicated amounts of pEGFP-mRZ1 (B, C, RZ) or pEGFP (E, F, GFP). The uterine horns were removed on day 5 pc and processed for immunohistochemistry using
mEMP2 antiserum (A–C, E, F) or the corresponding preimmune serum (D). Magnification: 400×.
437M. Wadehra et al. / Developmental Biology 292 (2006) 430–441significantly lower than that in the control horns (P b 0.01;
Wilcoxon matched pairs test) (Fig. 9A).
To ensure that the results we obtained using the hyper-
stimulated mouse model accurately reflected the situation in
mice cycling normally, we repeated the in vivo transfection
experiments on non-hyperstimulated mice. Females were
housed singly with males until the morning a vaginal plug
was observed. On the afternoon of day 1 pc, in vivo transfection
of the uterine horns was performed using 10 μg or 20 μg m-
shRNA. As before, the contralateral horn in each female was
injected with the same amount (10 μg or 20 μg) of control h-
shRNA plasmid. As expected, the mean number of implantation
sites in the control horns of normally cycling mice was lower
than that seen in hyperstimulated mice. When only 10 μg
shRNA was transfected, we did not observe a significant
difference in the number of implantation sites between the
uterine horns. However, similar to our results with hyperstimu-
lated mice, normally cycling mice had an obvious reduction in
implantation sites in the horns treated with 20 μg m-shRNA
targeting EMP2 as compared to h-shRNA (Fig. 9B). Together
with the results obtained using the ribozyme constructs, these
data using the shRNA constructs suggest an absolute require-
ment for EMP2 expression for successful implantation in the
mouse.
Discussion
Implantation is the end result of a tightly orchestrated series
of interactions between a receptive uterus and a mature
blastocyst (Norwitz et al., 2001). Although some endometrial
molecules involved in controlling these interactions have beenidentified (Lessey, 2002; Paria et al., 2002), a unifying
mechanism remains evasive. Here, we demonstrate that EMP2
is expressed at the endometrial surface and in decidualized
stromal cells in the peri-implantation period and that its
expression is likely required for mouse implantation. Combined
with studies of EMP2 and related proteins in other cell types,
these findings lead us to hypothesize that EMP2 affects
expression of endometrial cell surface proteins that are required
for successful embryo attachment and early steps of invasion.
This idea is supported by our data demonstrating that down-
regulation of EMP2 expression in endometrial cells inhibits
their ability to support mouse blastocyst attachment in vitro and
implantation in vivo.
In addition to its endometrial expression pattern, EMP2 is
also expressed in the embryonic trophectoderm on day 6 pc
(Fig. 2). These findings are consistent with our studies of
preimplantation embryos in which EMP2 is most highly
expressed in the trophectoderm of the expanded and hatched
blastocyst stages (Wadehra, Braun, and Williams, unpublished
results). The function of EMP2 in the embryo itself is the
subject of another study. We would like to point out, however,
that in the studies reported here the attaching/implanting
embryos were not exposed to the ribozyme or shRNA plasmids
because the in vivo transfections were performed on day 1 pc
when the embryos were located in the oviducts; embryos do not
enter the uterine horns until between day 3 and 4 pc. Because
we observed a clear decrease in EMP2 protein levels in the
endometrium in response to the active ribozyme or shRNA
treatments by day 4 pc, we interpret our results to be an effect of
the plasmid constructs on endometrial and not embryo EMP2
expression.
Fig. 6. Effect of ribozyme-mediated inhibition of EMP2 expression on implantation in vivo. (A) Appearance of nontransfected uterine horns on day 8 pc. (B)
Appearance of uterine horns on day 8 pc after transfection on day 1 pc with control (arrowhead) or active (arrow) construct. (C) Uterine horns were transfected with
pEGFP (GFP), pEGFP-mRZ1 (RZ), or not transfected (no DNA), and implantation sites per horn were counted on day 8 pc. The graph shows the mean number of
implantation sites ± SE in uterine horns transfected with the indicated amount of DNA. Implantation sites in at least 10 uterine horns were counted for each group.
Significant differences in the numbers of implantation sites between GFP- and RZ-transfected horns were observed at all doses (*P b 0.01). GFP-transfected or control
nontransfected right horn, black bars; RZ-transfected or control nontransfected left horn, white bars.
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endometrium could explain its importance in implantation.
In several other cell types, changes in EMP2 expression and
localization cause pleiotropic changes in the proteins
expressed on the plasma membrane (Wadehra et al., 2002,
2003a). Of note, EMP2 regulates the expression of integrins,Fig. 7. Effect of shRNA transfection on EMP2 expression. NIH 3T3 cells stably
overexpressing mouse EMP2 were transfected with h-shRNA or m-shRNA, as
indicated. After 48 h, the cells were collected and protein extracts
immunoblotted using hEMP2 antiserum. The blots were stripped and reprobed
with actin to document even protein loading (lower panel).membrane proteins whose cyclic regulation appears to be
critical for implantation (Lessey et al., 2000). In NIH 3T3
cells, increasing the expression of EMP2 upregulates the
surface expression of integrin α6β1 while downregulating
α5β1, resulting in an increase in the ability of these cells to
adhere to laminin (Wadehra et al., 2002). In the uterus, the
decidualized stroma responds to the implanting embryo by
upregulating the expression of laminin and integrins α1β1,
α4β1, and αvβ3 (Sutherland et al., 1993; Thomas et al.,
2002). Based on our observation that EMP2 expression in
the endometrial stroma was upregulated at the time of
implantation (Figs. 1 and 2), it is possible that these
alterations in stromal integrin expression are mediated by
EMP2. In fact, we demonstrated that, in human endometrial
cells, expression of integrin αvβ3 is directly correlated with
the level of EMP2 expression (Wadehra et al., 2005).
Furthermore, knockdown of EMP2 using in vivo transfection
of ribozyme or shRNA constructs resulted in a significant
Fig. 8. Effect of shRNA transfection on EMP2 expression in mouse endometrium. Uterine horns were transfected on day 1 pc with h-shRNA (A, B) or m-shRNA (C–
F). The uterine horns were removed on day 5 pc and processed for immunohistochemistry using mEMP2 antiserum (A–D) or the corresponding preimmune antiserum
(E, F). Magnification: 100× (A, C, E); 400× (B, D, F).
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trium (Wadehra et al., 2005). Together with the data
reported here, these results suggest that EMP2 expressionFig. 9. Effect of shRNA transfection on implantation. Uterine horns were transfected d
sites per horn were counted on day 8 pc. The graphs show the mean number of impl
number of pairs of uterine horns counted in each group is indicated at the base of this required for the appropriate expression of integrin αvβ3
(and potentially other endometrial molecules) during the
implantation window in vivo.ay 1 pc with the indicated amount of either h-shRNA or m-shRNA. Implantation
antation sites ± SE in uterine horns transfected with the indicated construct. The
e black bars. (A) Hyperstimulated females. (B) Normally cycling females.
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effects on expression of other proteins, it also could be involved
in the morphological reorganization of the endometrial cell
surface that includes membrane flattening and formation of
uterodomes, also known as the “plasma membrane transforma-
tion” (Murphy, 2004). In HEK 293 cells, overexpression of
EMP2 (or related GAS3/PMP22 family proteins) causes
“blebbing”, a process characterized by the protrusion from the
cell surface of large membrane bound vesicles (Hagmann et al.,
1999; Wilson et al., 2002). In nontransfected HEK 293 cells,
blebbing occurs in response to activation of the P2X7 purinergic
receptor, a protein reported to physically interact with EMP2
and to depend on EMP2 for its actions (Wilson et al., 2002). The
connection of EMP2 with a signaling pathway that results in
major morphological changes of the cell membrane in cultured
cells suggests that EMP2 could be involved in a similar
signaling pathway in the endometrium that results in transfor-
mation of the epithelial plasma membrane structure.
One other tetraspan protein, CD9, which is distantly related
to EMP2, is involved in mammalian reproduction. CD9−/− mice
display a defect in sperm–egg binding and fusion at fertilization
(Le Naour et al., 2000; Miyado et al., 2000). Importantly, these
mice also display a defect in sperm transport into the oviduct,
suggesting that sperm adhesion to the endometrial and/or
oviductal epithelium is impaired. CD9 is expressed in human
and bovine endometrium and interacts with specific integrin
subunits in these tissues based on co-localization and
immunoprecipitation assays (Park et al., 2000; Xiang and
MacLaren, 2002). In contrast to EMP2, CD9 expression does
not vary with the human menstrual cycle, so it is unlikely that
CD9 specifically regulates the expression of endometrial
surface proteins important for implantation (Park et al., 2000).
However, together with the results presented above, these
findings support a role for tetraspan proteins including EMP2
and CD9 in regulating the adhesive properties of the female
reproductive tract epithelium.
The inability to synchronize processes involved in embryo–
endometrium interactions results in a failure of implantation and
may account for up to 75% of pregnancies lost (Norwitz et al.,
2001). It is interesting to speculate that disruption of protein
trafficking or epithelial remodeling due to inappropriate EMP2
expression in the endometrium may explain some of these
losses. In any case, understanding the cell biological processes
associated with EMP2 and other tetraspan proteins in the female
reproductive tract may provide the scientific underpinnings for
the generation of novel therapeutic modalities designed to
alleviate infertility, enhance fetal health, and improve contra-
ceptive methods.
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